VRDN VIRIDIAN THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, VIRIDIAN THERAPEUTICS INC reported revenue of $284K (up 278.7% from a year earlier), net income of −$127M and diluted EPS of n/a; over the last four quarters revenue was $71.1M and net income −$387M; for the fiscal year ended December 2025 revenue was $70.8M, up 23359.9% on the year before.

VRDN annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $70.8M, gross profit n/a, operating income −$363M, net income −$343M (margin -483.6%), EPS n/a
• Fiscal year ended Dec 2024: revenue $302K, gross profit n/a, operating income −$299M, net income −$270M (margin -89370.9%), EPS n/a
• Fiscal year ended Dec 2023: revenue $314K, gross profit n/a, operating income −$254M, net income −$238M (margin -75700.6%), EPS −$5.31
• Fiscal year ended Dec 2022: revenue $1.77M, gross profit n/a, operating income −$134M, net income −$130M (margin -7330.7%), EPS −$4.05
• Fiscal year ended Dec 2021: revenue $2.96M, gross profit n/a, operating income −$79.7M, net income −$79.4M (margin -2679.7%), EPS −$6.66

VRDN quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $284K (up 278.7% year over year), net income −$127M, EPS n/a
• Quarter ended Mar 31, 2026: revenue $141K (up 95.8% year over year), net income −$105M, EPS n/a
• Quarter ended Dec 31, 2025 (from the annual report): revenue $132K (up 83.3% year over year), net income −$120M, EPS n/a
• Quarter ended Sep 30, 2025: revenue $70.6M (up 81958.1% year over year), net income −$34.6M, EPS n/a
• Quarter ended Jun 30, 2025: revenue $75.0K (up 4.2% year over year), net income −$101M, EPS n/a
• Quarter ended Mar 31, 2025: revenue $72.0K (up 0.0% year over year), net income −$86.9M, EPS n/a
• Quarter ended Dec 31, 2024 (from the annual report): revenue $72.0K (up 0.0% year over year), net income −$79.7M, EPS n/a
• Quarter ended Sep 30, 2024: revenue $86.0K (up 19.4% year over year), net income −$76.7M, EPS −$1.15
• Quarter ended Jun 30, 2024: revenue $72.0K (up 0.0% year over year), net income −$65.0M, EPS −$1.02
• Quarter ended Mar 31, 2024: revenue $72.0K (down 26.5% year over year), net income −$48.5M, EPS −$0.79
• Quarter ended Dec 31, 2023 (from the annual report): revenue $72.0K (down 31.4% year over year), net income −$66.8M, EPS −$1.34
• Quarter ended Sep 30, 2023: revenue $72.0K (down 94.0% year over year), net income −$47.7M, EPS −$1.09
• Quarter ended Jun 30, 2023: revenue $72.0K (down 71.9% year over year), net income −$55.1M, EPS −$1.27
• Quarter ended Mar 31, 2023: revenue $98.0K (down 54.6% year over year), net income −$68.2M, EPS −$1.61
• Quarter ended Dec 31, 2022 (from the annual report): revenue $105K (down 50.9% year over year), net income −$45.8M, EPS −$1.15
• Quarter ended Sep 30, 2022: revenue $1.20M (up 474.5% year over year), net income −$28.9M, EPS −$0.86
• Quarter ended Jun 30, 2022: revenue $256K (down 76.5% year over year), net income −$29.5M, EPS −$1.06
• Quarter ended Mar 31, 2022: revenue $216K (down 85.1% year over year), net income −$25.7M, EPS −$0.98
• Quarter ended Dec 31, 2021 (from the annual report): revenue $214K, net income −$28.9M, EPS −$0.29
• Quarter ended Sep 30, 2021: revenue $208K, net income −$14.0M, EPS −$1.25

VRDN cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$276M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$232M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$184M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$93.8M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$54.6M, share buybacks n/a

VRDN balance sheet

• Jun 30, 2026: cash n/a, total assets $1.10B, total liabilities $435M, shareholders' equity $662M
• Mar 31, 2026: cash n/a, total assets $789M, total liabilities $153M, shareholders' equity $636M
• Dec 31, 2025: cash n/a, total assets $899M, total liabilities $177M, shareholders' equity $722M
• Sep 30, 2025: cash n/a, total assets $577M, total liabilities $74.2M, shareholders' equity $503M, long-term debt $20.9M
• Jun 30, 2025: cash n/a, total assets $582M, total liabilities $67.2M, shareholders' equity $515M, long-term debt $12.4M
• Mar 31, 2025: cash n/a, total assets $661M, total liabilities $56.5M, shareholders' equity $604M, long-term debt $20.7M
• Dec 31, 2024: cash n/a, total assets $742M, total liabilities $70.8M, shareholders' equity $672M, long-term debt $20.6M
• Sep 30, 2024: cash n/a, total assets $772M, total liabilities $64.4M, shareholders' equity $707M, long-term debt $20.5M

What is VRDN's revenue?

VIRIDIAN THERAPEUTICS INC reported $71.1M of revenue over its last four quarters, through June 30, 2026.

Is VRDN profitable?

No. VIRIDIAN THERAPEUTICS INC lost $387M over the last four quarters.

VRDN ownership and insider trades · All stocks